|
Day 1
Monday, November 13, 2006
8:00-8:30 Pre-Conference Registration and Morning Coffee
8:30-11:30 Pre-Conference Workshop
–
|
Dynamic Resource and Portfolio Management within
the New Experimental Medicine Paradigm
|
This workshop will explore why the changing world of pharma and biotech R&D requires a more dynamic approach to resource and portfolio management and how modern simulation approaches using Bayesian statistical ideas can help managers to get the best out of their portfolio while actively managing down individual project risks. With the introduction of exploratory clinical trials, adaptive protocols, and translational medicine, attrition rates are now (i) changing, (ii) increasingly uncertain, (iii) more amenable to active management through explicit investments to fill critical knowledge gaps. These gaps often include the real biological relevance of the target, side-effects pharmacology, or the need to identify likely responders in advance of treatment. This workshop will demonstrate how, by analyzing the information and time effects of experimental medicine on potential projects, and therefore understanding the impact of filling these knowledge gaps, managers can maximize both the potential of their drug portfolio and the early development technologies at their disposal, including how to:
I. Present and visualize the key therapeutic benefits and late failure liabilities - the benefit/risk profile of potential drugs - as a set of options within the portfolio
II. Visualize the uncertainty associated with each option and reveal the extent to which expected portfolio values are particularly sensitive to risk that might be controllable
II. Analyze the potential impact of new information on project and portfolio values, to see where new translational medicine tasks could add greatest value - which types of investigations, which candidates?
IV. Incorporate realistic views of time to execute and reliability of results (false negatives/ false positives)
V. Revise both the candidate portfolio and the specific commitments to experimental medicine to get the best out of both candidates (or licenses) and the development capabilities available
As well as introducing participants to the underling principles, and some working models for exploring these risks and benefits, the workshop will use specific examples of drug development, including R&D under extreme time pressure such as a pandemic, to explore the risk verses benefits of different R&D paths.
Presenter: Andrew Chadwick, D. Phil, PA Consulting Group
|
12:00 Main Conference Registration
1:00 Chairperson’s Opening Remarks
 1:15 Designing Strategic Resource Management Systems Specifically for Pharma R&D
The challenges of time and cost to market coupled with increasing competition and regulatory hurdles have caused the pharmaceutical industry to focus more than ever on ensuring their R&D resources are leveraged and aligned with portfolio strategies. Questions arise around which activities are priority and when deliverables are needed, ultimately leading to the issue of resource constraints. Many companies have developed portfolio and resource management infrastructures (governance and technical solutions) to ensure their R&D efforts are appropriately prioritized and resources leveraged. This session will illustrate one company’s experience in combining the virtues of governance, a technical solution and focused project management to enable efficient and visible resource management. Attendees will discover that the most effective levers for successful implementation of the technical solution are:
- Clear objectives
- Project governance structure
- Detailed project plans
- Collaborative execution
Rob Neufelder, Director, Life Sciences, Integrated Project Management Company
2:00 Resource Management in Co-development Alliances - Opportunities and Challenges
- Pharmaceutical and Biopharma product portfolios are increasingly more dependent on strategic alliances
- Managing resources in these partnerships provides both opportunities - for example, the ability to leverage resources from the combined partnership, and challenges –(i.e. multiple partnerships contractually constrain resource available to internal programs
- This presentation will focus on defining those challenges and opportunities and outline ways that Biogen Idec manages resources in partnerships
Philip J. Gotwals, Ph.D., Senior Director, Program and Alliance Management,
Biogen Idec
2:45 Networking Refreshment Break
3:15 Strategic Resource Allocation in a Dynamic Business Environment
After attending this session, attendees will understand:
- How to measure and anticipate changes in loading on key resources
- How to adjust strategic capacity in line with changes in demand
- How to size the resource base for the likely demand and fluctuations
- The similarities and differences between process-based and project-based resource allocation
- How the specific case of pharmacovigilence capacity planning can be generalized for other situations
Colin Cornhill, MS, Senior Director, BRM Integration & Capacity Management, Johnson & Johnson
4:00 Rational Change: Using the Balanced Scorecard to Drive Intentionality and Accountability in Mergers, Acquisitions, and Organizational Restructuring
- Shift from the static-state, "parachute in" consulting model of assess-diagnose-intervene to a more rational, iterative model that clearly drives actions and outcomes
- Align organizational strategy with enterprise change efforts such as mergers, acquisition, and corporate restructuring
- Using existing performance management systems as a change effort "diagnosis engine"
- Demand accountability for change objectives from management, staff, and consultants
Joseph Logan, IT Services Change Group, AstraZeneca Pharmaceuticals
4:45 Roundtable Discussions
Concurrent round tables to discuss some of the more broad yet poignant questions facing the industry.
|
 |
Optimization and Management of Resources in a Pharmaceutical Outsourcing Industry: A Direct Comparison Between a Big Pharma Co. and a
CRO
Facilitator: Krish Ghosh, Ph.D., MBA, Vice President, Global Resource Management, Covance, (formerly, Director, Project Planning, Wyeth)
|
|
|
 |
Project and Portfolio Prioritization:
Best Practices in Redesigning Stage Gate Management Criteria
Moderator: Mark Schindler, Chief Technology & Innovation Officer, Visual
i|o,
Inc.
|
|
|
 |
Resource Forecasting and Management in the Pharmaceutical Industry
Modertator: Keith Vadas, President and CEO, ProModel Corporation
|
|
|
 |
Optimizing Resource Allocation to Efficiently Drive the Most Promising Projects
Facilitator: Richard M. Bayney, Ph.D., MSc, MBA, Vice President, Portfolio Planning, Pharmaceutical Research & Development, Johnson & Johnson
|
|
|
 |
Integrate Portfolio & Resource Management - Linkage to Workforce Capacity Planning
Facilitator:
Helen Hangac, Ph.D., Executive Director, Pfizer Global R&D, Pfizer, Inc.
|
5:45 Networking Cocktail Reception
Accreditation
Available
|
